Wall $t Banker$$

[micasey123]

RMTI - Rockwell Medical Technologies, Inc. Receives European Patent Issuance for Proprietary Iron-Delivery Technology
Wednesday April 19, 8:00 am ET


WIXOM, Mich., April 19 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI - News), a leading, innovative hemodialysis products manufacturer in the healthcare industry, reported that the European Patent and Trademark Office has issued a patent for Rockwell's proprietary iron-delivery product SFP, which covers the "Method and Pharmaceutical Composition for Iron Delivery in Hemodialysis and Peritoneal Dialysis Patients." Rockwell reported on August 10, 2005 that the EPTO had allowed its claims for the proprietary drug/device.




Rockwell's proprietary product SFP is designed to provide physiological iron replacement in ESRD patients by delivering iron via dialysate during hemodialysis and peritoneal dialysis treatment. Rockwell has licensed the exclusive rights to the SFP patent and is in the process of seeking FDA approval to market the product.

The countries the patent grant will affect are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

Compared to intravenous (IV) iron administration, results based on an FDA approved Phase II Study have shown that delivering iron via dialysate is a safer and more effective method for maintaining iron balance in dialysis patients, while at the same time eliminating associated nursing and pharmaceutical IV iron administration costs. Rockwell estimates that the U.S. dialysis market for IV iron delivery represents $450 million annually while the global market potential is approximately $750 million annually. Upon FDA market approval, Rockwell expects SFP to compete aggressively for those markets. Visit Rockwell's website at http://www.rockwellmed.com/ironnews.htm for more information on SFP.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, "This European patent issuance was expected based on the allowance we had previously received. It is a significant step for Rockwell as it enables us to protect our proprietary technology in a major market. Currently, we are making solid progress in our FDA development process and we expect to achieve several more significant milestones as we work towards market approval."